Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from SinoMab Bioscience Ltd. ( (HK:3681) ).
SinoMab BioScience Limited has scheduled a board meeting for 23 March 2026 to review, consider and approve the audited final results of the group for the financial year ended 31 December 2025. The board will also address any other business at the meeting, setting the stage for the upcoming release of the company’s annual financial performance to the market.
The announcement signals the company’s progression toward its regular financial reporting cycle, which will provide shareholders and potential investors with updated insight into SinoMab’s operational and financial health. The timing of the meeting indicates when the market can expect disclosure of full-year results, an event that may influence investor sentiment and trading in the company’s shares.
The most recent analyst rating on (HK:3681) stock is a Sell with a HK$1.50 price target. To see the full list of analyst forecasts on SinoMab Bioscience Ltd. stock, see the HK:3681 Stock Forecast page.
More about SinoMab Bioscience Ltd.
SinoMab BioScience Limited is a Hong Kong-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange under stock code 3681. The company operates through a group structure and is led by Executive Director, Chairman and Chief Executive Officer Dr. Shui On Leung, supported by a board comprising executive, non-executive and independent non-executive directors.
Average Trading Volume: 5,180,272
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.61B
For detailed information about 3681 stock, go to TipRanks’ Stock Analysis page.